Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for
patients with certain haematological cancers, with multiple CAR T cell products currently …

Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with
chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This …

For over two decades, the EBMT has updated recommendations on indications for
haematopoietic cell transplantation (HCT) practice based on clinical and scientific …

Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …

PURPOSE CD19 chimeric antigen receptor (CD19-CAR) T cells induce high response rates
in children and young adults (CAYAs) with B-cell acute lymphoblastic leukemia (B-ALL), but …

PURPOSE CD19-targeted chimeric antigen receptor T cells (CD19-CAR) and blinatumomab
effectively induce remission in relapsed or refractory B-cell acute lymphoblastic leukemia …

Several current immunotherapy approaches target private neoantigens derived from
mutations that are unique to individual patients' tumors. However, immunotherapeutic …

Relapsed acute lymphoblastic leukemia (ALL) has remained challenging to treat in children,
with survival rates lagging well behind those observed at initial diagnosis. Although there …

PURPOSE We determined the safety and efficacy of coadministration of CD19-and CD22-
chimeric antigen receptor (CAR) T cells in patients with refractory disease or high-risk …

Tisagenlecleucel therapy has shown promising efficacy for relapsed/refractory (R/R) B-cell
precursor acute lymphoblastic leukemia (BCP-ALL). However, relapses occur in 30–50% of …